🌟 Welcome Pranali Taskar to Deciduous Therapeutics! 🌟 Pranali brings to the team experience in immuno-oncology, neuro-inflammation, and cardiovascular research. We are excited for her to join us in our mission to treat age-related diseases using immune therapy.
Deciduous Therapeutics
Biotechnology Research
San Francisco, California 2,551 followers
Deciduous is developing a novel class of immune-modulatory therapies designed to promote a healthy lifespan.
About us
Senescent cells, which are characterized by irreversible damage and an inflammatory secretome, are considered a key driving force behind many age-related diseases. Due to a failure in immune surveillance, senescent cells accumulate and impact their local environment by inducing inflammation and promoting extracellular matrix remodeling, thus resulting in a myriad of metabolic and fibrotic consequences. Therefore, enabling the removal of senescent cells dramatically ameliorates disease pathologies in many age-related diseases, leading to overall improvements in health-span. At Deciduous Therapeutics, we have discovered novel molecules that can activate a critical endogenous immune surveillance mechanism to selectively remove senescent cells and thereby treat several classes of age-related diseases.
- Website
-
http://www.deciduoustx.com
External link for Deciduous Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Francisco, California
- Type
- Privately Held
Locations
-
Primary
Get directions
953 Indiana St
San Francisco, California 94107, US
Employees at Deciduous Therapeutics
Updates
-
Deciduous Therapeutics is excited to be speaking at the Longevity Global Summit Dec. 5-6th at the Buck Institute for Research on Aging. Learn more and register at https://lnkd.in/gx8Q8mYT
-
-
Deciduous Therapeutics will be at the Seno-Therapeutics Summit alongside John Lewis, Kelsey Moody, PhD, MBA, Amit Sharma, and Marco Quarta in the Early Stage Companies in Seno Therapeutics session. We hope to see you there!
-
-
We are excited to work with The Alliance for Longevity Initiatives on our mission to extend health span! 🌳
A4LI would not be who we are today without the help of numerous individuals and organizations that believe in what we are doing. That is why, every month, we use our platform to shine a spotlight on those that are making a profound impact on the longevity community. This month, we would like to recognize Deciduous Therapeutics for their unwavering commitment to combating age-related diseases. Since 2018, Deciduous has been at the forefront of developing therapies targeting senescent cells, a significant contributor to numerous age-related ailments. They believe that by harnessing the power of the human immune system, they can selectively eliminate harmful senescent cells and promote healthy human lifespan. As an organization founded on the mission of advancing next-generation therapies, we would like to applaud Deciduous for their groundbreaking efforts in the fight against age-related diseases. At A4LI, we take immense pride in working alongside them as we work towards a future where everyone can enjoy a longer, healthier life.
-
-
Please join me in congratulating Nadia Khan, PhD on her promotion to Senior Scientist! 🥂
-
-
Thanks to everyone for tolerating my senescence dad jokes 😂
Many thanks to Daniela Bakula and Morten Scheibye-Knudsen for inviting Deciduous Therapeutics to present at #ardd2023. ARDD is one of the single best events of the year and it is amazing to see such a cross section of promising academics, early stage companies, and a few of the early aging companies now reading out clinical data. ARDD is five days of wall to wall science and somehow it only gets better as the days go 😎
-
-
Many thanks to Daniela Bakula and Morten Scheibye-Knudsen for inviting Deciduous Therapeutics to present at #ardd2023. ARDD is one of the single best events of the year and it is amazing to see such a cross section of promising academics, early stage companies, and a few of the early aging companies now reading out clinical data. ARDD is five days of wall to wall science and somehow it only gets better as the days go 😎
-
-
There is still time to register for the Longevity+DeSci Summit in NYC this week! Friday, August 11th from 3:10 - 3:50 PM (ET), CEO of Maxwell Biosciences, Joshua McClure, Co-CEO of Cyclarity Therapeutics, Matthew "Oki" O'Connor, and our very own Robin Mansukhani will be discussing the keys to building a sustainable longevity company. We hope to see you there 😎 Conference info: https://lnkd.in/dAYRRB8w
-
-
We are honored for the opportunity to showcase our work alongside this impressive cohort of longevity entrepreneurs. Thank you to the Longevity Investors organizers; we're excited to see you in September!
We are thrilled to announce the selected start-ups for the Longevity Investors Conference 2023 🧬: BEYOND GENOMiX, Luminous Labs, Twinn Health, Neurxstem, MitoRx Therapeutics, Deciduous Therapeutics, and NeuroEM. Join us to witness the brightest minds and most promising ventures that are reshaping the future of longevity 🚀 Find out more here: https://lnkd.in/dUSrdgfT #LongevityInvestors
-